Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Alphamab Oncology (9966.HK)
Suzhou, CN
Alphamab Oncology operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, production, and market introduction of biological therapies for cancer. Its comprehensive product pipeline includes several key assets: KN046, a bispecific monoclonal antibody (BsAb) designed to inhibit immune checkpoints, is currently in pivotal Phase III clinical trials, targeting the clinically validated PD-L1 and CTLA-4 pathways. Another significant candidate is KN026, a cutting-edge anti-human epidermal growth factor receptor 2 (HER2) BsAb. This therapy is undergoing Phase II clinical studies for HER2-positive breast cancers (with Phase I/II trials specifically for heavily pre-treated cases) and is also in Phase II for various HER2-positive solid tumors. Additionally, the company is advancing KN019, a CTLA-4-based immunosuppressant fusion protein in Phase II clinical trials, which holds potential for diverse applications in autoimmune conditions and immune disorders arising from cancer treatments. The pipeline also features KN035, an injectable PD-L1 inhibitor that has successfully concluded pivotal Phase II clinical trials for solid tumors exhibiting deficient mismatch repair/microsatellite instability-high characteristics and is now in pivotal Phase III trials for biliary tract cancer. Finally, KN052, an innovative bispecific antibody targeting both PD-L1 and OX40, is in Phase Ia/Ib clinical development for the treatment of advanced solid tumors. Established in 2008, Alphamab Oncology's headquarters are located in Suzhou, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.67% | -11.65% | +4.48% | -15.11% | -7.14% | +1.90% | +10.84% | -54.84% | -32.59% | -32.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-13.8% Q4'25: +194.8% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-170.6% Q4'25: +27.8% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-35.1% Q4'25: -46.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-27.1% Q4'25: -62.4% (vs Q4'23)
-
ROIC Biotechnology: -16.1%-30.8% Q4'25: -125.0% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-2.3% ★ Q4'25: -0.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.43× Q4'25: -0.26× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.99M
est: 821.1K (+508.0%)
|
—
est: 2.13M (-100.0%)
|
146.02M
est: 111.86M (+30.5%)
|
166.85M
est: 202.20M (-17.5%)
|
218.77M
est: 238.01M (-8.1%)
|
640.08M
est: 398.69M (+60.5%)
|
551.58M
est: 422.82M (+30.5%)
|
318.30M
302.16M – 334.44M
-24.7% YoY
|
682.74M
630.74M – 734.73M
+114.5% YoY
|
1.09B
1.04B – 1.15B
+59.9% YoY
|
| EBITDA |
-277.57M
est: -221.0K (-125,478.0%)
|
-390.47M
est: -573.5K (-67,983.6%)
|
-358.13M
est: -30.11M (-1,089.3%)
|
-391.83M
est: -54.43M (-619.8%)
|
-129.30M
est: -119.13M (-8.5%)
|
156.79M
est: -199.55M (+178.6%)
|
-86.31M
est: -211.63M (+59.2%)
|
-159.31M
-167.39M – -151.23M
+24.7% YoY
|
-341.71M
-367.74M – -315.69M
-114.5% YoY
|
-546.55M
-574.27M – -518.83M
-59.9% YoY
|
| EBIT |
-279.40M
est: -287.2K (-97,175.0%)
|
-409.45M
est: -745.3K (-54,840.6%)
|
-399.24M
est: -39.13M (-920.3%)
|
-432.37M
est: -70.74M (-511.3%)
|
-198.41M
est: -143.75M (-38.0%)
|
101.01M
est: -240.80M (+141.9%)
|
-149.32M
est: -255.37M (+41.5%)
|
-192.24M
-201.99M – -182.49M
+24.7% YoY
|
-412.35M
-443.76M – -380.95M
-114.5% YoY
|
-659.53M
-692.98M – -626.08M
-59.9% YoY
|
| Net Income |
-836.35M
est: -404.96M (-106.5%)
|
-427.77M
est: -466.70M (+8.3%)
|
-412.42M
est: -595.47M (+30.7%)
|
-325.72M
est: -400.94M (+18.8%)
|
-210.59M
est: -200.58M (-5.0%)
|
166.34M
est: -112.84M (+247.4%)
|
-110.99M
est: -96.10M (-15.5%)
|
370.46M
346.04M – 394.88M
+485.5% YoY
|
116.98M
109.27M – 124.69M
-68.4% YoY
|
165.73M
154.80M – 176.66M
+41.7% YoY
|
| SGA |
154.30M
est: 415.8K (+37,007.9%)
|
78.21M
est: 1.08M (+7,149.0%)
|
77.55M
est: 56.65M (+36.9%)
|
86.94M
est: 102.40M (-15.1%)
|
79.34M
est: 79.98M (-0.8%)
|
75.11M
est: 133.97M (-43.9%)
|
81.65M
est: 142.09M (-42.5%)
|
106.96M
101.54M – 112.39M
-24.7% YoY
|
229.43M
211.95M – 246.90M
+114.5% YoY
|
366.95M
348.34M – 385.56M
+59.9% YoY
|
| EPS |
-1.56
est: -0.41 (-279.1%)
|
-0.46
est: -0.47 (+3.0%)
|
-0.44
est: -0.61 (+27.3%)
|
-0.35
est: -0.41 (+14.1%)
|
-0.22
est: -0.21 (-5.6%)
|
0.17
est: -0.13 (+234.2%)
|
-0.12
est: -0.10 (-20.0%)
|
0.39
0.36 – 0.41
+485.5% YoY
|
0.12
0.11 – 0.13
-68.4% YoY
|
0.17
0.16 – 0.18
+41.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.34% | 220.6K | 0.59% |
| 2 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.04% | 31.3K | 0.74% |
| 3 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.03% | 95.7K | 0.74% |
| 4 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.03% | 157.2K | 0.55% |
| 5 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.03% | 97.5K | 0.72% |
| 6 | State Street SPDR S&P China ETF GXC | 0.01% | 62.8K | 0.59% |
| 7 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.96M | 0.06% |
| 8 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 83.7K | 0.65% |
| 9 | State Street SPDR S&P Emerging Asia Pacific ETF GMF | 0.01% | 35.9K | 0.49% |
| 10 | FlexShares Morningstar Emerging Markets Factor Tilt Index Fund TLTE | 0.01% | 23.7K | 0.58% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ting Xu | Founder, Executive Chairman & Chief Executive Officer | 8M | — |
| Yang Liu | Chief Operating Officer & Executive Director | 3M | female |
| Jing Han | Chief Commercial Officer | — | male |
| Lok Yee Chan | Joint Company Secretary | — | female |
| Mike Liu | Senior Vice President of Business Development | — | — |
| Qiulan Cheng | Joint Company Secretary | — | female |
| Rui Jiang | Joint Company Secretary | — | female |
| Fei Wang | Chief Financial Officer | — | male |
| Yumin Wan | Vice President of Government Affairs & Public Relations | — | male |
| Hongwei Wang | Chief Technology Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 9966.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
